Anthem Biosciences IPO Price: 5 Things To Know About Drugmaker’s Public Issue Before It Opens For Subscription

Anthem Biosciences’ initial public offering (IPO) will open for subscription on July 14, 2025. Ahead of the opening of the subscription window, here are five key things to know about Anthem Biosciences IPO.

Anthem Biosciences IPO: Issue Price and Key Dates

Anthem Biosciences’ IPO is worth Rs 3,395 crore. The pharmaceutical company’s offer size consists entirely of an offer-for-sale (OFS) of 59.60 million shares.

Anthem Biosciences IPO price band has been fixed at Rs 540-570 per share. Retail investors can apply for the issue by placing bids for a minimum lot size of 26 shares which aggregates to an investment of Rs 14,040.

The minimum lot size for Small Non Institutional Investors (sNII) is 14 lots or 364 shares which amounts to an investment of Rs 2,07,480. The lot size for big non-institutional investors(bNIIs) is 68 lots or 1,768 shares which translates to an investment of  Rs 10,07,760.

Anthem Biosciences has reserved 50 per cent of the net offer size for the qualified institutional buyers. The drug maker has reserved as much as 35 per cent of the net issue for retail individual investors and 15 per cent of the net issue has been reserved for the non-institutional investor (NII) category.

Anthem Biosciences IPO share allotment status is likely to be finalised on July 17. Subsequent to the allotment of shares, refunds will be initiated for unsuccessful bidders on July 18, while successful bidders will receive shares of Anthem Biosciences in their demat accounts on the same day. Shares of the contract drug manufacturer will debut on the NSE and BSE. The CDMO’s shares are expected to list on the exchanges on July 21.

Anthem Biosciences: Key Financials

Anthem Biosciences’ revenue from operations increased by 30 per cent to Rs 1930.29 crore on March 31, 2025 compared to Rs 1483.07 crore at the end of March 31, 2024. The company’s profit-after-tax (PAT) surged nearly 23 per cent to Rs 451.26 crore at the end of FY 2024-25 compared to Rs 367.31 crore in the preceding fiscal. The net worth of the company grew by over 25 per cent to Rs 2,409.86 crore in FY25 compared to Rs 1,924.66 crore in FY24.

Anthem Biosciences: Key Competitors

The company mentioned in its RHP that the contract research, development, and manufacturing organization (CRDMO) market is highly fragmented and has over  1,000 to 1,500 global contract research organization (CROs) and CDMOs competing with each other for market share as of March, 2025. 

Some of the company’s key competitors in India include Syngene International Ltd, Sai Life Sciences Ltd, Cohance Lifesciences Ltd, Divi's Laboratories Ltd, Aragen Life Sciences Ltd. In China the company has three competitors namely: Wuxi AppTec Co. Ltd, Asymchem Laboratories (Tianjin) Co. Ltd., Pharmaron Beijing Co. Ltd). The company also faces competition from five competitors namely Siegfried Holding AG,  Lonza Group AG, Catalent Inc. PolyPeptide Group AG and Bachem Holding AG.

Anthem Biosciences: Business Model

Anthem Biosciences states in its RHP that it is a tech-concentrated Contract Research, Development and Manufacturing Organization (CRDMO). The company added that its operations span across several stages of the drug manufacturing process such as  drug discovery, development and manufacturing.

Anthem Biosciences added that it is one of the few companies domestically to have integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities. The company claimed in its RHP that it functions as a one-stop service provider and caters to a diverse range of customers including emerging biotech companies and large pharmaceutical companies.